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Abstract 
Objective: To evaluate the impact pharmacist-provided screening and education had on patient knowledge of osteoporosis and 
preventive strategies. 
Methods: A prospective, randomized, controlled study was conducted at 16 locations of a national supermarket chain pharmacy in 
the Richmond, Virginia area.  Women 30 years and older with no history of osteoporosis were enrolled in the study.  Patients self-
selected into the study by agreeing to the bone density screening, pharmacist-provided education, and completion of a knowledge 
survey.  Subjects were randomized to complete the osteoporosis-related knowledge survey either before (Group A) or after (Group B) 
the screening and education session.  The survey was developed after guideline and literature evaluation and was pretested with a 
group of patients for content and clarity.  The survey evaluated knowledge of osteoporosis, risk factors for the disease, appropriate 
age for testing, and preventive strategies.  Groups A and B were compared using t-tests. 
Results: A total of 110 women were enrolled in the study.  The mean (±SD) age was 52.5 ± 13.1 years in Group A (n=52) and 52.7 ± 
11.5 years in Group B (n=58).  Knowledge scores were higher in the group who received pharmacist-provided education prior to 
completing the survey in each category (knowledge of the disease, risk factors, preventive strategies, and appropriate age for testing) 
and overall (p<0.001). 
Conclusions: Community pharmacist-provided osteoporosis screening and education increased patient knowledge about osteoporosis 
and preventive strategies. Community pharmacist involvement with increasing patient knowledge may empower patients to engage 
in prevention strategies to improve bone mass. 
 
 
Introduction 
Osteoporosis is a disease in which bone mass and strength is 
reduced over time, increasing bone fragility and leading to 
more frequent fractures.1 Osteoporosis affects 10 million 
people in the United States, and another 33.6 million have 
low bone mass.2  Risk of osteoporosis increases with age and 
is greater in women than men; therefore, screening of at-risk 
populations is critical.2  The gold standard for measuring and 
diagnosing conditions of low bone density is a dual-energy x-
ray absorptiometry (DXA) scan.  Evaluation of bone mineral 
density (BMD) with a DXA scan is recommended for women 
older than 65 years and men older than 70 years, adults with  
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a fracture after 50 years, and anyone older than 50 years with 
risk factors for low bone mass.1,2 Osteoporosis can be treated 
with prescription medications and nonprescription calcium 
supplements, and it can also be prevented.  Maintaining 
adequate calcium and vitamin D intake, performing proper 
weight-bearing exercise, and not smoking or consuming 
excessive alcohol are important for prevention of the 
disease.2   
 
The National Osteoporosis Foundation (NOF) recommends 
that all women be informed of the risk factors for 
osteoporosis, because early screening and proper preventive 
measures are critical to avoid fractures.1 This call for a well-
informed population warrants a community-based screening 
and education program targeting women and girls of all ages. 
Quantitative ultrasonography using portable heel scanners is 
recommended by the United States Preventive Task Force as 
Original Research PRACTICE-BASED RESEARCH 
 
http://z.umn.edu/INNOVATIONS                      2015, Vol. 6, No. 3, Article 213                        INNOVATIONS in pharmacy   2 
 
a portable alternative to the DXA for predicting future 
fracture risk and are therefore appropriate for screening.3    
 
Community pharmacists, as highly accessible health care 
providers, have effectively screened patients using heel 
ultrasonometers and used the results to provide education 
and to refer high-risk patients to physicians for further 
evaluation and management.4-7  Patients participating in 
osteoporosis screening services conducted by community 
pharmacists were satisfied with the service.8-9  Several studies 
evaluated the effect pharmacist-provided osteoporosis 
screenings had on patient behaviors, such as discussing their 
screening result with a physician or taking calcium 
supplements.  These studies found that pharmacist 
intervention resulted in favorable behaviors.4,10-13  However, 
the literature does not contain studies that evaluate the 
impact of pharmacist-provided screening and education on 
women’s knowledge of osteoporosis or strategies for 
prevention.  Increasing patient knowledge of osteoporosis 
and preventive strategies may provide the tools to prevent 
the disease and improve bone mass.  
 
Objective 
The objective of this study was to evaluate the impact 
pharmacist-provided osteoporosis screening and education 
has on patient knowledge of osteoporosis and strategies for 
prevention. 
 
Methods 
A prospective, randomized, controlled study was conducted 
at 16 locations of a national supermarket chain pharmacy 
providing clinical services in the Richmond, Virginia area. The 
recruitment phase lasted from November 2012 to February 
2013.  Two osteoporosis screening sessions lasting 2 hours 
each were conducted at each of the 16 locations from 
January 2013 to February 2013. 
 
The study was approved by the Virginia Commonwealth 
University Institutional Review Board.  The survey collected 
demographic information and answers to knowledge 
assessment questions.  Information was collected to about 
potential risk factors for osteoporosis and included 
menopausal status, current calcium and/or vitamin D 
supplement usage, and family history of osteoporosis.  
Whether or not the patient was a healthcare provider was 
collected as a demographic to evaluate the potential for 
underlying knowledge.    
 
The knowledge portion of the survey (Appendix A) was 
developed using the NOF guidelines as a foundation.  
According to these guidelines, all women should be aware of 
adequate calcium and vitamin D intake, physical activity, 
tobacco and alcohol cessation as prevention strategies for 
osteoporosis.1  Basic pathophysiology, major risk factors, and 
long-term risks of osteoporosis were also identified as 
important items for the survey.1  In addition, national 
recommendations for screening of women were selected for 
inclusion.1-3  Once developed and agreed upon by all authors, 
the survey was pretested with a group of patients for content 
and clarity.  
 
The survey contained ten questions that evaluated 
knowledge of osteoporosis, characteristics that predispose 
people to the disease, the appropriate age for testing, and 
knowledge of preventive strategies, including weight-bearing 
exercise, adequate consumption of calcium and vitamin D, 
and sources of these nutrients.  Each knowledge survey item 
was assigned one of the following categories: osteoporosis 
knowledge, knowledge of risk factors, preventive strategies, 
and appropriate age for osteoporosis testing.  
 
Screening sessions were advertised to customers of the 
supermarket and pharmacy using fliers throughout the store 
and employees' verbal referral at the prescription point of 
sale.  Patients were able to schedule appointments via 
telephone, however; patients did not have to have an 
appointment to attend the screening session. Patients self-
selected into the study by agreeing to the bone density 
screening and completing the knowledge survey.  The 
inclusion criteria were female gender, age ≥30 years, and a 
medical history absent of osteoporosis.   However, all women 
interested in the screening and education session were 
provided the service, regardless of whether they agreed to 
participate in the study. 
 
Patients were randomized using a random number table 
containing a list of 250 entries of either 1 or 2.  The primary 
author generated the table prior to the first screening, and 
each patient was randomized into Group A or Group B, as 
indicated by the table (1=Group A; 2=Group B).  Group A took 
the knowledge survey before the screening and education 
service was provided by the pharmacist.  Group B received 
the screening and education service provided by the 
pharmacist, followed by the knowledge survey.  Patients 
were not asked to complete the knowledge survey both pre- 
and post-intervention, since the time points would have been 
too close together for adequate evaluation in one patient.  
 
The primary author conducted all of the screening sessions 
which were approximately 15 minutes and included screening 
with the Achilles Express heel ultrasonometer, education, and 
survey completion.14  The Achilles Express heel 
ultrasonometer manual stratifies T-scores into three 
categories:  low risk (≥-1), moderate risk (-1.1 to -2.5), and 
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high risk (≤-2.5) of future fractures.14  These scores lined up 
with the WHO definitions for T-score results of normal bone 
mass, low bone mass, and compromised bone mass, 
measured by DXA devices.1 
 
Standardized verbal education was provided and included 
information about the result of the heel scan and 
osteoporosis.  Osteoporosis information was obtained from 
multiple sources and included the following; general 
osteoporosis description, characteristics that predispose 
people to the disease, the appropriate age for testing, and 
common preventive strategies.1-3  No patients who were 
screened and received education paid for the service, 
regardless of whether they chose to complete the survey. 
 
The knowledge survey was scored by the primary author.  
Each survey item was marked correct or incorrect, with 
fractional scores assessed for multi-part questions.  Each item 
in Group A was compared to Group B using t-tests both in 
each category as well as for overall score.  Subsequently, each 
group was stratified into risk category groups, as indicated by 
their screening results.  Low-risk and moderate-risk 
subgroups were analyzed using t-tests to detect differences in 
knowledge scores between the subgroups. 
 
Results 
A total of 110 women were enrolled in the study, screened 
for risk of future fractures, provided education, and surveyed 
for their knowledge.  There were no significant differences in 
baseline demographics observed.  The mean (±SD) age was 
52.5 ± 13.1 years in Group A (n=52) and 52.7 ± 11.4 years in 
Group B (n=58).  Demographics for patients were self-
reported (see Table 1).   
 
The majority of patients (50.9%) reported not taking a 
calcium supplement, vitamin D supplement, or supplements 
that contain both medications. However, 37.3% of patients 
reported taking calcium and vitamin D supplements, 0.9% 
taking calcium supplements only, and 10.9% taking vitamin D 
only.  Patients reported that physicians had recommended 
both supplements (30%), calcium only (2.7%), vitamin D only 
(14.5%), or neither supplement (52.7%) to them.   
 
Overall, 100 patients’ results indicated a low risk of future 
fractures, and 10 patients tested at moderate risk of future 
fractures.  No study patients fell into the high-risk category. 
 
Performance on the knowledge survey improved in all 
categories in the group taking the survey after pharmacist 
education.  Total score, or overall knowledge, also improved 
in the group who received pharmacist education before the 
survey (Figure 1). 
When each group was stratified into those at low risk of 
future fractures and those who had moderate risk of future 
fractures, knowledge scores were similar.  In Group A, overall 
knowledge score was 44.5% for those at low risk and 38.4% in 
those at moderate risk (p = 0.207).  In Group B, overall 
knowledge score was 77.7% for those at low risk and 73.6% 
for those at moderate risk (p = 0.775). 
 
Discussion 
The literature contains studies which show that pharmacists 
are capable of screening, educating, and referring patients at 
risk for osteoporosis in the community setting.4-13 In this 
study and previous studies, the education provided by 
pharmacists included an overview of osteoporosis, 
appropriate calcium and vitamin D intake, lifestyle measures 
for prevention (i.e. weight-bearing exercise, smoking 
cessation), and results from screenings performed.4-9;11-13  
Previous studies also included additional topics for patient 
education which are most appropriate when targeting an 
elderly population or a population already diagnosed with 
osteoporosis, like home safety and medications for 
treatment.6,7  The duration of the education sessions in this 
study was appropriate, based on the previous literature citing 
education sessions  between 10 and 20 minutes.5,6,10,13   
 
However, the literature is absent of studies evaluating the   
impact of a pharmacist provided osteoporosis screening and 
education service on patient knowledge.  This study 
demonstrated the pharmacist’s ability to screen women for 
risk of future fractures and provide focused education within 
a 15-20 minute session.  Furthermore, the results 
demonstrated that patient knowledge of the disease, risk 
factors, preventive measures, and age for testing increased 
after pharmacist intervention.  Patient knowledge of risk 
level, risk factors, and preventive measures have been 
associated with positive lifestyle modifications and lower fall 
risk, which may, in turn, augment fracture risk.15-18 
 
Patients screened in this study had an average age of 52.6 
years consistent with other studies with similar inclusion 
criteria, ages ranging from 47.5 to 59.6 years.4,5,10,12   Bone 
mass loss accelerates after menopause, and screening and 
educating patients prior to this time is a best practice to avoid 
disease.1,2  The fact that mean age fell toward the low end of 
this range may be accounted for by the inclusion criterion of 
a medical history absent of osteoporosis. 
 
The largest improvement in knowledge was seen with the 
question that addressed the age by which all women should 
receive testing for osteoporosis, 6.9% in Group A and 69% in 
Group B (p<0.001).  This data shows that there is a deficit in 
women’s knowledge about appropriate age for osteoporosis 
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testing.  Pharmacists providing this information to patients 
may help increase the number of women being screened for 
this disease at the age recommended in the NOF guidelines.1 
 
In Group A, a larger proportion (26.9%) of patients reported 
to be healthcare professionals than in Group B (19%).  The 
proportion of patients who reported being healthcare 
professionals was larger in the group who took the survey at 
baseline, which supported the result that the pharmacist 
intervention improved knowledge despite a potential for 
higher baseline knowledge.  However, all patients self-
selected into the study, which may have meant that they 
were generally more health conscious and may have had 
higher baseline knowledge than the general public.  The 
statistically significant increase in knowledge between groups 
indicates that the pharmacist intervention was effective 
despite this issue, but results may not be generalizable to the 
whole population. 
 
The results of this study did not indicate that there was a 
significant difference between knowledge of patients with 
low risk of future fractures and those with moderate risk of 
future fractures (A:  p=0.207; B:  p=0.775).  However, there 
was a very small sample size of patients at moderate risk of 
future fractures, and this study was not designed to evaluate 
this endpoint.  Numerically, scores were lower in patients at 
moderate risk of future fractures (Group A:  44.5% vs. 38.4%; 
Group B:  77.7% vs. 73.6%).  No study patients fell into the 
high risk category, which may be because the inclusion 
criteria stated patients should have a self-reported medical 
history absent of osteoporosis.  Some previous studies in 
community pharmacies focused on the older women or post-
menopausal women only, which would likely result in more 
patients in the higher risk categories.6-8,11,13  Other studies 
that did not focus on women of older age allowed inclusion of 
women with diagnosed osteoporosis, which would also 
increase the number of high-risk scan results.4-5,10 
 
The pharmacist is a highly accessible health care provider 
who can serve as an effective advocate for screening, 
treatment, and education for osteoporosis.  As community 
pharmacists’ role in healthcare evolves, the education they 
are capable of providing to patients may be used to 
contribute to better bone health outcomes and lower 
healthcare costs overall. 
 
Limitations 
The most significant limitation to this study was that the 
knowledge survey used was not validated.  In addition, 
patients self-selected into the pharmacist provided screening 
and education service.  Patients likely to self-select into the 
study may be more health conscious overall, which may skew 
the results of their scans and knowledge survey results 
compared to the general population.  Demographic data 
collected was also based on patient self-report.  Finally, the 
knowledge survey was administered immediately following 
the pharmacist-provided screening and education.  Ideally, 
the knowledge would have been evaluated in a follow-up 
several weeks later, to better evaluate retention of 
knowledge.  This would likely be better linked to prevention 
of disease, since knowledge retained would have a greater 
impact if employed over time (e.g. weight-bearing exercise, 
calcium and vitamin D supplementation).  
 
Conclusions 
Community pharmacist-provided osteoporosis screening and 
education increased patient knowledge about osteoporosis, 
its risk factors, its preventive strategies, and the age by which 
women should be tested.  Further studies that evaluate 
knowledge retained after a community screening and 
education service are warranted.  
 
References 
1. National Osteoporosis Foundation. Clinician’s Guide 
to Prevention and Treatment of Osteoporosis.  2013.  
Available at 
http://nof.org/files/nof/public/content/resource/91
3/files/580.pdf.  Last accessed January 14, 2014 
2. US Department of Health and Human Services. Bone 
Health and Osteoporosis: A Report of the Surgeon 
General. Rockville, MD: US Department of Health 
and Human Services, Office of the Surgeon General; 
2004. 
3. Screening for Osteoporosis. Recommendation 
Statement. United States Preventive Task Force. 
Available at 
http://www.uspreventiveservicestaskforce.org/uspst
f10/osteoporosis/osteors.htm  Last accessed January 
11, 2014. 
4. Goode JR, Swiger K, Bluml B.  Regional Osteoporosis 
Screening, Referral, and Monitoring Program in 
Community Pharmacies:  Findings from Project 
ImPACT:  Osteoporosis.  J Am Pharm Assoc. 
2004;44:152-160. 
5. Liu Y, Nevins JC, Carruthers KM, et al. Osteoporosis 
risk screening for women in a community pharmacy. 
J Am Pharm Assoc. 2007;47(4):521-526. 
6. Johnson JF, Koenigsfeld C, Hughell L, et al. Bone 
health screening, education, and referral project in 
northwest Iowa: creating a model for community 
pharmacies. J Am Pharm Assoc. 2008;48(3):379-387. 
 
 
Original Research PRACTICE-BASED RESEARCH 
 
http://z.umn.edu/INNOVATIONS                      2015, Vol. 6, No. 3, Article 213                        INNOVATIONS in pharmacy   5 
 
7. Yuksel N, Majumdar SR, Biggs C, et al.  Community 
pharmacist-initiated screening program for 
osteoporosis:  randomized controlled trial.  
Osteoporos Int. 2010;21(3):391-8. 
8. MacLaughlin EJ, MacLaughlin AA, Snella KA, et al. 
Osteoporosis screening and education in community 
pharmacies using a team approach. 
Pharmacotherapy. 2005;25(3):379-386. 
9. Lai LK, Armstrong EP, Salcido AL, et al. Women’s 
perception of bone-mineral density testing and 
osteoporosis education in the community pharmacy. 
Consult Pharm. 2003;18(11):968-976. 
10. Summers KM, Brock TP. Impact of pharmacist-led 
community bone mineral density screenings. Ann 
Pharmacother. 2005;39(2):243-248. 
11. Naunton M, Peterson GM, Jones G. Pharmacist-
provided quantitative hee ultrasound screening for 
rural women at risk of osteoporosis. Ann 
Pharmacother. 2006;40(1):38-44. 
12. Peters S, Singla D, Raney E. Impact of pharmacist-
provided osteoporosis education and screening in 
the workplace. J Am Pharm Assoc. 2006;46(2):216-
218. 
13. McConaha JL, Berdine HJ, Skomo ML, et al. Impact of 
the fracture risk assessment on patient and 
physician behavior in osteoporosis prevention. J 
Pharm Pract. 2014;27(1):25-30. 
14. ACHILLES EXPRESS:  Bone Ultrasonometer [Internet].  
Madison (WI):  GE Lunar Corporation; Accessed 2013 
June 1. Available from: www.gemedicalsystems.com. 
15. Sale JE, Gignac MA, Hawker G, et al.  Non-
pharmacological strategies used by patients at high 
risk for future fracture to manage fracture risk--a 
qualitative study. Osteoporos Int. 2014;25(1):281-
288. 
16. Burke-Doe A, Hudson A, Werth H, et al. Knowledge 
of osteoporosis risk factors and prevalence of risk 
factors for osteoporosis, falls, and fracture in 
functionally independent older adults. J Geriatr Phys 
Ther. 2008;31(1):11-7. 
17. Francis KL, Matthews BL, Van Mechelen W, et al. 
Effectiveness of a community-based osteoporosis 
education and self-management course: a wait list 
controlled trial. Osteoporos Int. 2009;20(9):1563-70. 
18. Laslett LL, Lynch J, Sullivan TR, et al. Osteoporosis 
education improves osteoporosis knowledge and 
dietary calcium: comparison of a 4 week and a one-
session education course. Int J Rheum Dis. 
2011;14(3):239-47.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Original Research PRACTICE-BASED RESEARCH 
 
http://z.umn.edu/INNOVATIONS                      2015, Vol. 6, No. 3, Article 213                        INNOVATIONS in pharmacy   6 
 
 
 
 
Table 1:  Self-reported Patient Demographics 
 Group A No 
(%) 
(n=52) 
Group B No 
(%) 
(n=58) 
Total (%) 
(n=110) 
p-value 
Mean Age ± SD  
 52.5 ± 13.1 52.7 ± 11.4 52.6 0.937 
Menopausal status  
Pre-menopausal 17 (32.7) 17 (29.3) 34 (30.9) 0.5486 
Peri-menopausal 8 (15.4) 16 (27.6) 24 (21.8) 0.1434 
Post-menopausal 27 (51.9) 25 (43.1) 52 (47.3) 0.2745 
Race  
American Indian/Alaska Native 0 (0) 1 (1.7) 1 (0.9) 0.3137 
Asian 1 (1.9) 0 (0) 1 (0.9) 0.2462 
Black 6 (11.5) 16 (27.6) 22 (20) 0.0445 
Hispanic 1 (1.9) 1 (1.7) 2 (1.8) 0.6777 
Native Hawaiian/Pacific Islander 0 (0) 0 (0) 0 (0) n/a 
White/Caucasian 43 (82.7) 40 (69.0) 83 (75.5) 0.0746 
Other 1 (1.9) 0 (0) 1 (0.9) 0.2462 
Education level  
Some high school 0 (0) 1 (1.7) 1 (0.9) 0.3137 
High school diploma/GED 13 (25) 14 (24.1) 27 (24.5) 0.689 
Some college 8 (15.4) 12 (20.7) 20 (18.2) 0.4834 
Associate’s degree 5 (9.6) 3 (5.2) 8 (7.3) 0.2975 
Bachelor’s degree 11 (21.1) 11 (19.0) 22 (20) 0.598 
Master’s degree 5 (9.6) 10 (17.2) 15 (13.6) 0.2613 
Professional degree 9 (17.3) 7 (12.1) 16 (14.5) 0.3429 
Yearly household income  
<$10,000 2 (3.8) 3 (5.2) 5 (4.5) 0.6334 
$10,001 - $25,000  9 (17.3) 9 (15.5) 18 (16.4) 0.614 
$25,001 - $40,000 5 (9.6) 17 (29.3) 22 (20) 0.0131 
$40,001 - $55,000 8 (15.4) 6 (10.3) 14 (12.7) 0.3379 
$55,001 - $70,000 4 (7.7) 3 (5.2) 7 (6.4) 0.4707 
>$70,000 15 (28.8) 18 (31) 33 (30) 0.7389 
Family history of osteoporosis  
Yes 16 (30.8) 25 (43.1) 41 (37.3) 0.2899 
No 24 (46.2) 25 (43.1) 49 (44.5) 
Unknown 12 (23.1) 8 (13.8) 20 (18.2) 
Healthcare professional  
Yes 14 (26.9) 11 (19.0) 25 (22.7) 0.2978 
No 38 (73.1) 46 (79.3) 84 (76.4) 
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Figure 1:  Knowledge Score Comparison 
*Statistically significant difference in score, p<0.001 
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Appendix A 
This survey is voluntary.   
Please check the box next to the category that best applies to you. 
Please select which category describes you best: 
 Pre-menopausal (not yet going through menopause) 
 Peri-menopausal (currently going through menopause) 
 Post-menopausal (already experienced menopause) 
Age:  
_________________ 
Please select which race/ethnicity describes you best: 
 African-American/Black 
 Asian 
 American Indian/Alaska Native 
 Native Hawaiian/Pacific Islander 
 White/Caucasian  
 Other:  _____________________________ 
Please select the highest level of education you have achieved: 
 Some high school 
 High school diploma/GED 
 Some college 
 Associates degree 
 Bachelor’s degree 
 Master’s degree 
 Professional/doctoral degree 
 Other:  _____________________________ 
Please select your total yearly household income: 
 <$10,000 
 $10,001 – $25,000 
 $25,001 – $40,000 
 $40,001 – $55,000 
 $55,001 – $70,000 
 >$70,000 
Do you currently take calcium or vitamin D supplements? 
 Yes, calcium + vitamin D 
 Yes, calcium only 
 Yes, vitamin D only 
 No, neither 
Has a doctor ever recommended that you take calcium or vitamin D supplements? 
 Yes, calcium + vitamin D 
 Yes, calcium only 
 Yes, vitamin D only 
 No, neither 
Do you have a family history of osteoporosis? 
 Yes 
 No  Unsure 
Are you a healthcare professional? 
 Yes  No 
Please circle the letter next to the answer you select as correct. 
1. What is osteoporosis? 
a. Tiny holes in bone 
b. Swelling causing weakening of the major joints (like the knees and hips) 
c. Greater bone removal than replacement, causing weaker bones 
d. Chronic pain in the lower back 
2. Women reach highest (peak) bone mass at what age? 
a. 4-5 years 
b. Puberty 
c. 30 years 
d. Just before menopause 
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3. Risk of developing osteoporosis is higher in (check all that apply): 
 Men 
 Women 
 Those who are thin 
 Those who are overweight 
 Those 65 years and older 
 Those younger than 65 years 
 Those who use alcohol 
 Those who use tobacco products 
 Those with a family history of the disease 
 Those who are White/Caucasian  
 Those who are Asian 
 Those who are African-American/black 
 Those who are Hispanic 
4. Which of the following can help maintain bone strength?  Check all that apply. 
 High-impact exercise (i.e. running) 
 Low-impact exercise (i.e. swimming) 
 Weight lifting 
 Water aerobics 
 Yoga 
 Fish oil supplements 
 Calcium supplements 
 Vitamin A supplements 
 Discontinuing use of tobacco products 
 Discontinuing use of alcohol 
5. True or False?  Bone and joint pain is a common symptom of osteoporosis. 
a. True 
b. False 
6. How much calcium should you take in every day to prevent osteoporosis? 
a. 600 mg 
b. 800 mg 
c. 1000 mg 
d. 1200 mg 
7. What is the recommended amount of vitamin D you should have every day? 
a. 400 IU 
b. 600 IU 
c. 800 IU 
d. 1000 IU 
8. Which of the following foods contain the most calcium per serving? 
a. Nuts (almonds, walnuts, etc.) 
b. Dark green, leafy vegetables 
c. Milk 
d. Lean protein sources (chicken, lean beef, etc.) 
9. All women should begin to be tested for osteoporosis with a bone scan at what age? 
a. 40 years 
b. 50 years 
c. 65 years 
d. 75 years 
10. Which of the following are the long-term risks of osteoporosis? 
a. Bone and joint pain 
b. Increased falls 
c. Bone fractures 
d. Need for knee replacement 
Thank you for your participation in this survey. 
 
 
